ROIVANT SCIENCES LTD (ROIV) Fundamental Analysis & Valuation

NASDAQ:ROIV • BMG762791017

Current stock price

29.08 USD
-0.75 (-2.51%)
At close:
29.08 USD
0 (0%)
After Hours:

This ROIV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. ROIV Profitability Analysis

1.1 Basic Checks

  • In the past year ROIV has reported negative net income.
  • In the past year ROIV has reported a negative cash flow from operations.
  • In the past 5 years ROIV reported 4 times negative net income.
  • In the past 5 years ROIV always reported negative operating cash flow.
ROIV Yearly Net Income VS EBIT VS OCF VS FCFROIV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 1B -1B 2B 3B 4B

1.2 Ratios

  • The Return On Assets of ROIV (-15.49%) is better than 77.91% of its industry peers.
  • ROIV has a Return On Equity of -18.96%. This is amongst the best in the industry. ROIV outperforms 82.75% of its industry peers.
Industry RankSector Rank
ROA -15.49%
ROE -18.96%
ROIC N/A
ROA(3y)4.94%
ROA(5y)-9.82%
ROE(3y)-5.99%
ROE(5y)-22.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROIV Yearly ROA, ROE, ROICROIV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 50 -50

1.3 Margins

  • The Gross Margin of ROIV (91.21%) is better than 92.44% of its industry peers.
  • In the last couple of years the Gross Margin of ROIV has remained more or less at the same level.
  • ROIV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.96%
GM growth 5Y-0.3%
ROIV Yearly Profit, Operating, Gross MarginsROIV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 5K 10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. ROIV Health Analysis

2.1 Basic Checks

  • ROIV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ROIV has been reduced compared to 1 year ago.
  • The number of shares outstanding for ROIV has been increased compared to 5 years ago.
  • ROIV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ROIV Yearly Shares OutstandingROIV Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
ROIV Yearly Total Debt VS Total AssetsROIV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 13.14 indicates that ROIV is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 13.14, ROIV belongs to the best of the industry, outperforming 84.30% of the companies in the same industry.
  • There is no outstanding debt for ROIV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.14
ROIC/WACCN/A
WACC9.25%
ROIV Yearly LT Debt VS Equity VS FCFROIV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 2B 4B

2.3 Liquidity

  • ROIV has a Current Ratio of 30.66. This indicates that ROIV is financially healthy and has no problem in meeting its short term obligations.
  • ROIV has a better Current ratio (30.66) than 97.67% of its industry peers.
  • ROIV has a Quick Ratio of 30.66. This indicates that ROIV is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 30.66, ROIV belongs to the best of the industry, outperforming 97.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 30.66
Quick Ratio 30.66
ROIV Yearly Current Assets VS Current LiabilitesROIV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ROIV Growth Analysis

3.1 Past

  • The earnings per share for ROIV have decreased strongly by -680.00% in the last year.
  • The Revenue for ROIV has decreased by -73.60% in the past year. This is quite bad
  • The Revenue for ROIV have been decreasing by -15.56% on average. This is quite bad
EPS 1Y (TTM)-680%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-265.22%
Revenue 1Y (TTM)-73.6%
Revenue growth 3Y-19.3%
Revenue growth 5Y-15.56%
Sales Q2Q%-84.03%

3.2 Future

  • Based on estimates for the next years, ROIV will show a very strong growth in Earnings Per Share. The EPS will grow by 50.70% on average per year.
  • Based on estimates for the next years, ROIV will show a very strong growth in Revenue. The Revenue will grow by 101.24% on average per year.
EPS Next Y-418.84%
EPS Next 2Y-141.7%
EPS Next 3Y-73.73%
EPS Next 5Y50.7%
Revenue Next Year-89.66%
Revenue Next 2Y-6.54%
Revenue Next 3Y80.51%
Revenue Next 5Y101.24%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ROIV Yearly Revenue VS EstimatesROIV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B
ROIV Yearly EPS VS EstimatesROIV Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. ROIV Valuation Analysis

4.1 Price/Earnings Ratio

  • ROIV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ROIV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ROIV Price Earnings VS Forward Price EarningsROIV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ROIV Per share dataROIV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • ROIV's earnings are expected to decrease with -73.73% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-141.7%
EPS Next 3Y-73.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ROIV Dividend Analysis

5.1 Amount

  • No dividends for ROIV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ROIV Fundamentals: All Metrics, Ratios and Statistics

ROIVANT SCIENCES LTD

NASDAQ:ROIV (4/20/2026, 8:00:02 PM)

After market: 29.08 0 (0%)

29.08

-0.75 (-2.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)N/A
Inst Owners67.97%
Inst Owner Change0.07%
Ins Owners3.76%
Ins Owner Change-1.25%
Market Cap20.81B
Revenue(TTM)13.31M
Net Income(TTM)-809.24M
Analysts86.32
Price Target33.66 (15.75%)
Short Float %4.81%
Short Ratio3.96
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)16.44%
Min EPS beat(2)-17.28%
Max EPS beat(2)50.15%
EPS beat(4)2
Avg EPS beat(4)9.05%
Min EPS beat(4)-17.28%
Max EPS beat(4)50.15%
EPS beat(8)5
Avg EPS beat(8)47.69%
EPS beat(12)7
Avg EPS beat(12)31.92%
EPS beat(16)9
Avg EPS beat(16)20.76%
Revenue beat(2)0
Avg Revenue beat(2)-73.78%
Min Revenue beat(2)-77.83%
Max Revenue beat(2)-69.72%
Revenue beat(4)0
Avg Revenue beat(4)-76.1%
Min Revenue beat(4)-86.28%
Max Revenue beat(4)-69.72%
Revenue beat(8)1
Avg Revenue beat(8)-44.64%
Revenue beat(12)4
Avg Revenue beat(12)-24.93%
Revenue beat(16)6
Avg Revenue beat(16)-17.24%
PT rev (1m)3.77%
PT rev (3m)23.47%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.59%
EPS NY rev (1m)-5.1%
EPS NY rev (3m)-1.09%
Revenue NQ rev (1m)-8.48%
Revenue NQ rev (3m)-43.02%
Revenue NY rev (1m)-1.96%
Revenue NY rev (3m)-47.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1563.68
P/FCF N/A
P/OCF N/A
P/B 4.87
P/tB 4.87
EV/EBITDA N/A
EPS(TTM)-1.17
EYN/A
EPS(NY)-1.46
Fwd EYN/A
FCF(TTM)-1.07
FCFYN/A
OCF(TTM)-1.06
OCFYN/A
SpS0.02
BVpS5.97
TBVpS5.97
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -15.49%
ROE -18.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.21%
FCFM N/A
ROA(3y)4.94%
ROA(5y)-9.82%
ROE(3y)-5.99%
ROE(5y)-22.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.96%
GM growth 5Y-0.3%
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 187.64%
Cap/Sales 58.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 30.66
Quick Ratio 30.66
Altman-Z 13.14
F-Score3
WACC9.25%
ROIC/WACCN/A
Cap/Depr(3y)35.38%
Cap/Depr(5y)N/A
Cap/Sales(3y)13.59%
Cap/Sales(5y)19.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-680%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-265.22%
EPS Next Y-418.84%
EPS Next 2Y-141.7%
EPS Next 3Y-73.73%
EPS Next 5Y50.7%
Revenue 1Y (TTM)-73.6%
Revenue growth 3Y-19.3%
Revenue growth 5Y-15.56%
Sales Q2Q%-84.03%
Revenue Next Year-89.66%
Revenue Next 2Y-6.54%
Revenue Next 3Y80.51%
Revenue Next 5Y101.24%
EBIT growth 1Y-11.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.64%
EBIT Next 3Y-1.4%
EBIT Next 5YN/A
FCF growth 1Y8.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.19%
OCF growth 3YN/A
OCF growth 5YN/A

ROIVANT SCIENCES LTD / ROIV Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ROIVANT SCIENCES LTD (ROIV) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ROIV.


Can you provide the valuation status for ROIVANT SCIENCES LTD?

ChartMill assigns a valuation rating of 0 / 10 to ROIVANT SCIENCES LTD (ROIV). This can be considered as Overvalued.


Can you provide the profitability details for ROIVANT SCIENCES LTD?

ROIVANT SCIENCES LTD (ROIV) has a profitability rating of 2 / 10.